{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:55:26Z","timestamp":1758257726232,"version":"3.44.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA164273"],"award-info":[{"award-number":["R01CA164273"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Venanzi Fund"},{"name":"Targeting a Cure for Lung Cancer Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Despite advances in ALK inhibitors for ALK fusion-positive (ALK+) non\u2013small-cell lung cancer (NSCLC), drug resistance remains a challenge. Studies of treatment outcomes and resistance biomarkers are imperative for drug development, yet patient representation can be limited. This study evaluated the feasibility of a decentralized research infrastructure to establish a clinical and biospecimen repository, broadening patient access and inclusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Patients with advanced ALK+ NSCLC across the United States were enrolled through remote informed consent. Clinical history and tumor molecular profiling data were collected at baseline and during remote follow-ups. Archival tumor and saliva biospecimens (for germline sampling) were obtained for analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 87 eligible patients, 80 (92%) completed remote consent and enrolled. The clinical data collection rate was 100%, with archival tumor acquired from 80% and saliva samples from 65%. Patients represented 31 states, with 94% residing outside the study center\u2019s state and 90% receiving care elsewhere. Next-generation sequencing was conducted on 55 treatment-na\u00efve and 18 treatment-resistant biopsies, all of whom received at least one prior second-generation ALK inhibitor, and 9 received lorlatinib. ALK resistance mutations were identified in 54% of treatment-resistant biopsies; other commonly co-altered genes included TP53 (18%) and CDKN2A\/B (16%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study highlights the feasibility of a decentralized design to enhance the inclusion of a broader patient population with ALK+ NSCLC. This establishes a scalable framework that may help overcome barriers to patient participation in research, with the goal of improving therapy development and patient outcomes. The Elucidating Novel Immune and Genomic Markers for ALK+ study accrual and analysis continue (NCT04881916).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf217","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:17:07Z","timestamp":1752585427000},"source":"Crossref","is-referenced-by-count":0,"title":["ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC"],"prefix":"10.1093","volume":"30","author":[{"given":"Joyce","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Medicine and Cancer Center, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Waliany","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cancer Center, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Do","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cancer Center, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cancer Center, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8302-3076","authenticated-orcid":false,"given":"Paige","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cancer Center, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cancer Center, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily S","family":"Venanzi","sequence":"additional","affiliation":[{"name":"ALK Positive, Inc ., Atlanta, GA, 30328,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-4081","authenticated-orcid":false,"given":"Justin F","family":"Gainor","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cancer Center, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-3916","authenticated-orcid":false,"given":"Jessica J","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cancer Center, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2025091815430205900_oyaf217-B1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"2025091815430205900_oyaf217-B2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Cancer"},{"key":"2025091815430205900_oyaf217-B3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"2025091815430205900_oyaf217-B4","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025091815430205900_oyaf217-B5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"2025091815430205900_oyaf217-B6","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Eng J Med"},{"key":"2025091815430205900_oyaf217-B7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025091815430205900_oyaf217-B8","doi-asserted-by":"crossref","first-page":"713530","DOI":"10.3389\/fonc.2021.713530","article-title":"The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer","volume":"11","author":"Pan","year":"2021","journal-title":"Front Oncol"},{"key":"2025091815430205900_oyaf217-B9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.20.02602","article-title":"Persistent disparity: socioeconomic deprivation and cancer outcomes in patients treated in clinical trials","volume":"39","author":"Unger","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025091815430205900_oyaf217-B10","doi-asserted-by":"crossref","first-page":"e2322515","DOI":"10.1001\/jamanetworkopen.2023.22515","article-title":"Racial and ethnic inequities in US oncology clinical trial participation from 2017 to 2022","volume":"6","author":"Pittell","year":"2023","journal-title":"JAMA Network Open"},{"key":"2025091815430205900_oyaf217-B11","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/1078-0432.CCR-23-1391","article-title":"Driving diversity and inclusion in cancer drug development\u2014industry and regulatory perspectives, current practices, opportunities, and challenges","volume":"29","author":"Fashoyin-Aje","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025091815430205900_oyaf217-B12","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025091815430205900_oyaf217-B13","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.1002\/cam4.5598","article-title":"Clinical value of second opinions in oncology: a retrospective review of changes in diagnosis and treatment recommendations","volume":"12","author":"Lipitz-Snyderman","year":"2023","journal-title":"Cancer Med"},{"key":"2025091815430205900_oyaf217-B14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/OP.22.00122","article-title":"The road less traveled: transportation barriers to cancer care delivery in the rural patient population","volume":"18","author":"Wercholuk","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2025091815430205900_oyaf217-B15","doi-asserted-by":"crossref","first-page":"100939","DOI":"10.1016\/j.conctc.2022.100939","article-title":"Barriers for cancer clinical trial enrollment: a qualitative study of the perspectives of healthcare providers","volume":"28","author":"Kumar","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"2025091815430205900_oyaf217-B16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1634\/theoncologist.2015-0110","article-title":"Distance as a barrier to cancer diagnosis and treatment: review of the literature","volume":"20","author":"Ambroggi","year":"2015","journal-title":"Oncologist"},{"year":"2025","author":"ENIGMA Study","key":"2025091815430205900_oyaf217-B17"},{"key":"2025091815430205900_oyaf217-B18","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.21037\/tlcr-22-713","article-title":"Patient-led advocacy in ALK-positive lung cancer","volume":"12","author":"Barton","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2025091815430205900_oyaf217-B19","first-page":"17","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Prec Oncol"},{"key":"2025091815430205900_oyaf217-B20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"2025091815430205900_oyaf217-B21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1047-2797(01)00267-8","article-title":"Generalizing molecular results arising from incomplete biological samples: expected bias and unexpected findings","volume":"12","author":"Porta","year":"2002","journal-title":"Ann Epidemiol"},{"key":"2025091815430205900_oyaf217-B22","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.2009.25.6065","article-title":"Sources of bias in specimens for research about molecular markers for cancer","volume":"28","author":"Ransohoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025091815430205900_oyaf217-B23","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3390\/cancers13081966","article-title":"Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-Na\u00efve ALK-positive lung cancer","volume":"13","author":"Chuang","year":"2021","journal-title":"Cancers"},{"key":"2025091815430205900_oyaf217-B24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamacardio.2020.0984","article-title":"Digital informed consent in a rural and low-income population","volume":"5","author":"Clark","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025091815430205900_oyaf217-B25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.2804","article-title":"Diversity, equity, and inclusion in clinical research: a path toward precision health for everyone","volume":"113","author":"Washington","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2025091815430205900_oyaf217-B26","first-page":"497","article-title":"Barriers to lung cancer care: health professionals\u2019 perspectives","volume":"25","author":"Dunn","year":"2017","journal-title":"Support Care Cancer"},{"key":"2025091815430205900_oyaf217-B27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/OP.20.00174","article-title":"Closing the rural cancer care gap: three institutional approaches","volume":"16","author":"Levit","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025091815430205900_oyaf217-B28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JOP.2013.001311","article-title":"Enhancing the American Society of Clinical Oncology workforce information system with geographic distribution of oncologists and comparison of data sources for the number of practicing oncologists","volume":"10","author":"Kirkwood","year":"2014","journal-title":"J Oncol Pract"},{"key":"2025091815430205900_oyaf217-B29","doi-asserted-by":"crossref","first-page":"e100726","DOI":"10.1136\/bmjhci-2022-100726","article-title":"Electronic consent in clinical care: an international scoping review","volume":"30","author":"Chimonas","year":"2023","journal-title":"BMJ Health Care Inform"},{"key":"2025091815430205900_oyaf217-B30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pedn.2023.05.010","article-title":"Consenting in the time of the COVID-19 pandemic","volume":"74","author":"Phillips","year":"2024","journal-title":"J Pediatr Nurs"},{"key":"2025091815430205900_oyaf217-B31","doi-asserted-by":"crossref","first-page":"e2200122","DOI":"10.1200\/CCI.22.00122","article-title":"Electronic consent at US Cancer Centers: a survey of practices, challenges, and opportunities","volume":"7","author":"Chimonas","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"key":"2025091815430205900_oyaf217-B32","doi-asserted-by":"crossref","first-page":"8205","DOI":"10.1097\/JS9.0000000000002132","article-title":"Enhancing postoperative care with telemedicine and remote monitoring for improved recovery and patient safety","volume":"110","author":"Jeyanthi","year":"2024","journal-title":"Int J Surg"},{"key":"2025091815430205900_oyaf217-B33","doi-asserted-by":"crossref","first-page":"e28285","DOI":"10.2196\/28285","article-title":"Remote monitoring systems for patients with chronic diseases in primary health care: systematic review","volume":"9","author":"Peyroteo","year":"2021","journal-title":"JMIR mHealth and uHealth"},{"key":"2025091815430205900_oyaf217-B34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2025091815430205900_oyaf217-B35","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025091815430205900_oyaf217-B36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41698-024-00498-w","article-title":"New pan-ALK inhibitor-resistant EML4: ALK mutations detected by liquid biopsy in lung cancer patients","volume":"8","author":"Villa","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2025091815430205900_oyaf217-B37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1186\/s12967-024-05388-0","article-title":"Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs","volume":"22","author":"Wu","year":"2024","journal-title":"J Transl Med"},{"key":"2025091815430205900_oyaf217-B38","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"2025091815430205900_oyaf217-B39","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov"},{"key":"2025091815430205900_oyaf217-B40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jtho.2023.08.007","article-title":"Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC","volume":"19","author":"Lara-Mej\u00eda","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2025091815430205900_oyaf217-B41","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/2767-9764.CRC-24-0065","article-title":"Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC","volume":"4","author":"Nakazawa","year":"2024","journal-title":"Cancer Res Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf217\/63790802\/oyaf217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf217\/63790802\/oyaf217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf217\/63790802\/oyaf217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:43:12Z","timestamp":1758224592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf217\/8205682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf217","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,17]]},"article-number":"oyaf217"}}